Sarah Sumner
Gerontology · Cairo, GANPI 1205398914
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations.
Across 105 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$378
- GSK$262
- AstraZeneca$224
- Pfizer$155
- CSL Behring$113
- Lilly USA, LLC$112
- plus $680 from 17 others
What the payments were for
- Food & beverage$1,925100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $378 |
| GSK | 14 | $262 |
| AstraZeneca | 13 | $224 |
| Pfizer | 8 | $155 |
| CSL Behring | 5 | $113 |
| Lilly USA, LLC | 7 | $112 |
| AbbVie | 6 | $104 |
| Dexcom, Inc. | 4 | $72 |
| Johnson & Johnson | 4 | $69 |
| Bayer | 3 | $62 |
| Corcept Therapeutics | 3 | $55 |
| Exact Sciences | 3 | $49 |
| Pharming Healthcare, Inc. | 2 | $39 |
| Amgen | 2 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Biohaven Pharmaceuticals, Inc. | 1 | $26 |
| Phathom Pharmaceuticals, Inc. | 2 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Merck | 1 | $16 |
| Inari Medical, Inc. | 1 | $15 |
| Inogen, Inc. | 1 | $7 |
How this compares
$1,925 in reported general payments places this provider in the 75th percentile of 197 gerontology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 86 | $116,247 |
| MounjaroTirzepatide | 54 | $72,655 |
| EliquisApixaban | 82 | $61,039 |
| TrulicityDulaglutide | 20 | $27,039 |
| FarxigaDapagliflozin Propanediol | 45 | $26,754 |
| EntrestoSacubitril/Valsartan | 14 | $15,457 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $11,298 |
| JanuviaSitagliptin Phosphate | 14 | $9,093 |
| JardianceEmpagliflozin | 16 | $8,807 |
| LinzessLinaclotide | 17 | $8,526 |
| XareltoRivaroxaban | 11 | $6,278 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $5,763 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $5,467 |
| RexultiBrexpiprazole | 15 | $5,452 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,212 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $378 | $116,24786 claims |
| Lilly USA, LLCMounjaro, Trulicity | $112 | $99,69374 claims |
| PfizerEliquis | $155 | $61,03982 claims |
| AstraZenecaFarxiga, Symbicort | $224 | $32,51764 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $262 | $15,51023 claims |
| MerckJanuvia | $16 | $9,09314 claims |
| AbbVieLinzess | $104 | $8,52617 claims |
| Johnson & JohnsonXarelto | $69 | $6,27811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 197 gerontology providers in Georgia.
Other gerontology in Cairo
- Carolyn ClevengerAtlanta$65K
- Mitzi LewisAtlanta$37K
- Constance MeinkenAtlanta$36K
- Britni JohnsonSavannah$24K
- Doreen AbrigoWarner Robins$14K
- Taylor SwineaWaycross$10K
- Michelle DudleyMacon$10K
- Kathleen BradfordAtlanta$8K
- Teresa VickersWarner Robins$6K
- Melissa RusterucciPeachtree City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.